Amgen's Nplate approved in EU for chronic ITP
This article was originally published in Scrip
Executive Summary
Amgen's Nplate (romiplostim) has been approved by the European Commission for refractory chronic immune (idiopathic) thrombocytopenic purpura (ITP) .